GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Beneish M-Score

Urologix (Urologix) Beneish M-Score : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Urologix Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Urologix's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Urologix was 0.00. The lowest was 0.00. And the median was 0.00.


Urologix Beneish M-Score Historical Data

The historical data trend for Urologix's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix Beneish M-Score Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.12 -3.75 7.92 -3.49 -8.36

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.85 -8.36 -8.11 -7.81 -7.32

Competitive Comparison of Urologix's Beneish M-Score

For the Medical Devices subindustry, Urologix's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Urologix's Beneish M-Score falls into.



Urologix Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Urologix for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9612+0.528 * 0.8884+0.404 * 0.5316+0.892 * 0.8059+0.115 * 0.8497
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6995+4.679 * -0.269759-0.327 * 2.0139
=-4.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar15) TTM:Last Year (Mar14) TTM:
Total Receivables was $1.39 Mil.
Revenue was 2.796 + 3.079 + 3.021 + 3.294 = $12.19 Mil.
Gross Profit was 1.311 + 1.464 + 1.462 + 1.583 = $5.82 Mil.
Total Current Assets was $3.40 Mil.
Total Assets was $5.02 Mil.
Property, Plant and Equipment(Net PPE) was $0.29 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.50 Mil.
Selling, General, & Admin. Expense(SGA) was $5.14 Mil.
Total Current Liabilities was $6.13 Mil.
Long-Term Debt & Capital Lease Obligation was $3.54 Mil.
Net Income was -0.349 + -0.357 + -0.437 + -3.525 = $-4.67 Mil.
Non Operating Income was -0.006 + -0.003 + -0.003 + -3.038 = $-3.05 Mil.
Cash Flow from Operations was -0.034 + 0.032 + -0.17 + -0.091 = $-0.26 Mil.
Total Receivables was $1.80 Mil.
Revenue was 3.356 + 3.806 + 3.779 + 4.185 = $15.13 Mil.
Gross Profit was 0.849 + 1.798 + 1.864 + 1.905 = $6.42 Mil.
Total Current Assets was $4.15 Mil.
Total Assets was $9.31 Mil.
Property, Plant and Equipment(Net PPE) was $0.53 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.62 Mil.
Selling, General, & Admin. Expense(SGA) was $9.11 Mil.
Total Current Liabilities was $4.49 Mil.
Long-Term Debt & Capital Lease Obligation was $4.41 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.392 / 12.19) / (1.797 / 15.126)
=0.114192 / 0.118802
=0.9612

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6.416 / 15.126) / (5.82 / 12.19)
=0.42417 / 0.477441
=0.8884

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.403 + 0.291) / 5.023) / (1 - (4.148 + 0.53) / 9.314)
=0.264583 / 0.497745
=0.5316

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=12.19 / 15.126
=0.8059

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.616 / (0.616 + 0.53)) / (0.501 / (0.501 + 0.291))
=0.537522 / 0.632576
=0.8497

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5.137 / 12.19) / (9.113 / 15.126)
=0.421411 / 0.602473
=0.6995

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.537 + 6.129) / 5.023) / ((4.413 + 4.487) / 9.314)
=1.924348 / 0.955551
=2.0139

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-4.668 - -3.05 - -0.263) / 5.023
=-0.269759

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Urologix has a M-score of -4.50 suggests that the company is unlikely to be a manipulator.


Urologix Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Urologix's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Urologix (Urologix) Business Description

Traded in Other Exchanges
N/A
Address
14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Executives
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet director, officer: CEO 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore director
Guy C Jackson director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon officer: Chief Technology Officer
Bobby Ivan Griffin director 1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo officer: VP, Product Dev. & Operations 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote director 649 SUMMIT AVENUE, ST PAUL MN 55105

Urologix (Urologix) Headlines

From GuruFocus

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-21-2009

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-17-2010

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares

By GuruFocus Research GuruFocus Editor 02-01-2011

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares

By GuruFocus Research GuruFocus Editor 12-07-2009